<?xml version='1.0' encoding='utf-8'?>
<document id="26041408"><sentence text="Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor."><entity charOffset="80-93" id="DDI-PubMed.26041408.s1.e0" text="Canagliflozin" /></sentence><sentence text="The sodium-glucose co-transporter 2 (SGLT2) inhibitors represent novel therapeutic approaches in the management of type 2 diabetes mellitus; they act on kidneys to decrease the renal threshold for glucose (RTG) and increase urinary glucose excretion (UGE)"><entity charOffset="4-18" id="DDI-PubMed.26041408.s2.e0" text="sodium-glucose" /><entity charOffset="197-204" id="DDI-PubMed.26041408.s2.e1" text="glucose" /><entity charOffset="206-209" id="DDI-PubMed.26041408.s2.e2" text="RTG" /><entity charOffset="232-239" id="DDI-PubMed.26041408.s2.e3" text="glucose" /><pair ddi="false" e1="DDI-PubMed.26041408.s2.e0" e2="DDI-PubMed.26041408.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26041408.s2.e0" e2="DDI-PubMed.26041408.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26041408.s2.e0" e2="DDI-PubMed.26041408.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26041408.s2.e0" e2="DDI-PubMed.26041408.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26041408.s2.e1" e2="DDI-PubMed.26041408.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26041408.s2.e1" e2="DDI-PubMed.26041408.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26041408.s2.e1" e2="DDI-PubMed.26041408.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26041408.s2.e2" e2="DDI-PubMed.26041408.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26041408.s2.e2" e2="DDI-PubMed.26041408.s2.e3" /></sentence><sentence text=" Canagliflozin is an orally active, reversible, selective SGLT2 inhibitor"><entity charOffset="1-14" id="DDI-PubMed.26041408.s3.e0" text="Canagliflozin" /></sentence><sentence text=" Orally administered canagliflozin is rapidly absorbed achieving peak plasma concentrations in 1-2 h"><entity charOffset="21-34" id="DDI-PubMed.26041408.s4.e0" text="canagliflozin" /></sentence><sentence text=" Dose-proportional systemic exposure to canagliflozin has been observed over a wide dose range (50-1600 mg) with an oral bioavailability of 65 %"><entity charOffset="40-53" id="DDI-PubMed.26041408.s5.e0" text="canagliflozin" /></sentence><sentence text=" Canagliflozin is glucuronidated into two inactive metabolites, M7 and M5 by uridine diphosphate-glucuronosyltransferase (UGT) 1A9 and UGT2B4, respectively"><entity charOffset="1-14" id="DDI-PubMed.26041408.s6.e0" text="Canagliflozin" /><entity charOffset="77-96" id="DDI-PubMed.26041408.s6.e1" text="uridine diphosphate" /><pair ddi="false" e1="DDI-PubMed.26041408.s6.e0" e2="DDI-PubMed.26041408.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26041408.s6.e0" e2="DDI-PubMed.26041408.s6.e1" /></sentence><sentence text=" Canagliflozin reaches steady state in 4 days, and there is minimal accumulation observed after multiple dosing"><entity charOffset="1-14" id="DDI-PubMed.26041408.s7.e0" text="Canagliflozin" /></sentence><sentence text=" Approximately 60 % and 33 % of the administered dose is excreted in the feces and urine, respectively" /><sentence text=" The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10"><entity charOffset="38-51" id="DDI-PubMed.26041408.s9.e0" text="canagliflozin" /></sentence><sentence text="6 and 13" /><sentence text="1 h, respectively" /><sentence text=" No clinically relevant differences are observed in canagliflozin exposure with respect to age, race, sex, and body weight" /><sentence text=" The pharmacokinetics of canagliflozin remains unaffected by mild or moderate hepatic impairment"><entity charOffset="25-38" id="DDI-PubMed.26041408.s13.e0" text="canagliflozin" /></sentence><sentence text=" Systemic exposure to canagliflozin is increased in patients with renal impairment relative to those with normal renal function; however, the efficacy is reduced in patients with renal impairment owing to the reduced filtered glucose load"><entity charOffset="22-35" id="DDI-PubMed.26041408.s14.e0" text="canagliflozin" /><entity charOffset="226-233" id="DDI-PubMed.26041408.s14.e1" text="glucose" /><pair ddi="false" e1="DDI-PubMed.26041408.s14.e0" e2="DDI-PubMed.26041408.s14.e0" /><pair ddi="false" e1="DDI-PubMed.26041408.s14.e0" e2="DDI-PubMed.26041408.s14.e1" /></sentence><sentence text=" Canagliflozin did not show clinically relevant drug interactions with metformin, glyburide, simvastatin, warfarin, hydrochlorothiazide, oral contraceptives, probenecid, and cyclosporine, while co-administration with rifampin modestly reduced canagliflozin plasma concentrations and thus may necessitate an appropriate monitoring of glycemic control"><entity charOffset="1-14" id="DDI-PubMed.26041408.s15.e0" text="Canagliflozin" /><entity charOffset="71-80" id="DDI-PubMed.26041408.s15.e1" text="metformin" /><entity charOffset="82-91" id="DDI-PubMed.26041408.s15.e2" text="glyburide" /><entity charOffset="93-104" id="DDI-PubMed.26041408.s15.e3" text="simvastatin" /><entity charOffset="106-114" id="DDI-PubMed.26041408.s15.e4" text="warfarin" /><entity charOffset="116-135" id="DDI-PubMed.26041408.s15.e5" text="hydrochlorothiazide" /><entity charOffset="158-168" id="DDI-PubMed.26041408.s15.e6" text="probenecid" /><entity charOffset="174-186" id="DDI-PubMed.26041408.s15.e7" text="cyclosporine" /><entity charOffset="217-225" id="DDI-PubMed.26041408.s15.e8" text="rifampin" /><entity charOffset="243-256" id="DDI-PubMed.26041408.s15.e9" text="canagliflozin" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e0" e2="DDI-PubMed.26041408.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e0" e2="DDI-PubMed.26041408.s15.e1" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e0" e2="DDI-PubMed.26041408.s15.e2" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e0" e2="DDI-PubMed.26041408.s15.e3" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e0" e2="DDI-PubMed.26041408.s15.e4" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e0" e2="DDI-PubMed.26041408.s15.e5" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e0" e2="DDI-PubMed.26041408.s15.e6" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e0" e2="DDI-PubMed.26041408.s15.e7" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e0" e2="DDI-PubMed.26041408.s15.e8" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e0" e2="DDI-PubMed.26041408.s15.e9" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e1" e2="DDI-PubMed.26041408.s15.e1" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e1" e2="DDI-PubMed.26041408.s15.e2" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e1" e2="DDI-PubMed.26041408.s15.e3" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e1" e2="DDI-PubMed.26041408.s15.e4" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e1" e2="DDI-PubMed.26041408.s15.e5" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e1" e2="DDI-PubMed.26041408.s15.e6" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e1" e2="DDI-PubMed.26041408.s15.e7" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e1" e2="DDI-PubMed.26041408.s15.e8" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e1" e2="DDI-PubMed.26041408.s15.e9" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e2" e2="DDI-PubMed.26041408.s15.e2" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e2" e2="DDI-PubMed.26041408.s15.e3" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e2" e2="DDI-PubMed.26041408.s15.e4" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e2" e2="DDI-PubMed.26041408.s15.e5" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e2" e2="DDI-PubMed.26041408.s15.e6" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e2" e2="DDI-PubMed.26041408.s15.e7" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e2" e2="DDI-PubMed.26041408.s15.e8" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e2" e2="DDI-PubMed.26041408.s15.e9" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e3" e2="DDI-PubMed.26041408.s15.e3" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e3" e2="DDI-PubMed.26041408.s15.e4" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e3" e2="DDI-PubMed.26041408.s15.e5" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e3" e2="DDI-PubMed.26041408.s15.e6" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e3" e2="DDI-PubMed.26041408.s15.e7" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e3" e2="DDI-PubMed.26041408.s15.e8" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e3" e2="DDI-PubMed.26041408.s15.e9" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e4" e2="DDI-PubMed.26041408.s15.e4" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e4" e2="DDI-PubMed.26041408.s15.e5" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e4" e2="DDI-PubMed.26041408.s15.e6" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e4" e2="DDI-PubMed.26041408.s15.e7" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e4" e2="DDI-PubMed.26041408.s15.e8" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e4" e2="DDI-PubMed.26041408.s15.e9" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e5" e2="DDI-PubMed.26041408.s15.e5" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e5" e2="DDI-PubMed.26041408.s15.e6" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e5" e2="DDI-PubMed.26041408.s15.e7" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e5" e2="DDI-PubMed.26041408.s15.e8" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e5" e2="DDI-PubMed.26041408.s15.e9" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e6" e2="DDI-PubMed.26041408.s15.e6" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e6" e2="DDI-PubMed.26041408.s15.e7" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e6" e2="DDI-PubMed.26041408.s15.e8" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e6" e2="DDI-PubMed.26041408.s15.e9" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e7" e2="DDI-PubMed.26041408.s15.e7" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e7" e2="DDI-PubMed.26041408.s15.e8" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e7" e2="DDI-PubMed.26041408.s15.e9" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e8" e2="DDI-PubMed.26041408.s15.e8" /><pair ddi="false" e1="DDI-PubMed.26041408.s15.e8" e2="DDI-PubMed.26041408.s15.e9" /></sentence><sentence text=" Canagliflozin increases UGE and suppresses RTG in a dose-dependent manner, thereby lowering the plasma glucose levels and reducing the glycosylated hemoglobin levels through an insulin-independent mechanism of action"><entity charOffset="104-111" id="DDI-PubMed.26041408.s16.e0" text="glucose" /><entity charOffset="44-50" id="DDI-PubMed.26041408.s16.e1" text="RTG" /><pair ddi="false" e1="DDI-PubMed.26041408.s16.e1" e2="DDI-PubMed.26041408.s16.e1" /><pair ddi="false" e1="DDI-PubMed.26041408.s16.e1" e2="DDI-PubMed.26041408.s16.e0" /></sentence><sentence text=" The 300-mg dose provides near-maximal effects on RTG throughout the full 24-h dosing interval, whereas the effect of the 100-mg dose on RTG is near-maximal for approximately 12 h and is modestly attenuated during the overnight period"><entity charOffset="50-52" id="DDI-PubMed.26041408.s17.e0" text="RTG" /><entity charOffset="137-139" id="DDI-PubMed.26041408.s17.e1" text="RTG" /><pair ddi="false" e1="DDI-PubMed.26041408.s17.e0" e2="DDI-PubMed.26041408.s17.e0" /><pair ddi="false" e1="DDI-PubMed.26041408.s17.e0" e2="DDI-PubMed.26041408.s17.e1" /></sentence><sentence text=" The observed pharmacokinetic/pharmacodynamic profile of canagliflozin in patients with type 2 diabetes mellitus supports a once-daily dosing regimen"><entity charOffset="57-70" id="DDI-PubMed.26041408.s18.e0" text="canagliflozin" /></sentence><sentence text=" " /></document>